We can only add our growing confidence in ultimately receiving SAMR approval for our infant formula to be sold into China. There are many significant initiatives underway at WHA and as each reaches a point of conclusion or significant progress, all shareholders in the general market will be advised. We are growingly confident of receiving SAMR approval.
Sam, happy new year and thank you for being a WHA shareholder.
Regards,
Peter Nesveda Corporate Affairs & International Investor Relations Wattle Health Australia Ltd (ASX: WHA)
17/71 Victoria Crescent Abbotsford Victoria 3067, Australia
This email was sent by Wattle Health Australia Ltd (ABN 77 150 759 363). You received this email because you have previously contacted us, purchased products from us, or asked to receive information and updates about our products. Our privacy policy is available on our website. You may unsubscribe by emailing [email protected]. If you have any questions about how we handle your personal information, please call us on 1300 88 79 69 (or +61 3 8399 9419 for international callers), or write to us at 17/71 Victoria Crescent, Abbotsford, Victoria 3067, Australia.